As mentioned previously, the completed phase I trial for the 68Ga-HER2 PET/CT nanobody spurred an ongoing phase II trial that will quantify the metastasis in breast carcinoma patients and assess repeatability (NCT03924466). Here, ERBB2 is linked to breast carcinoma.